ISARIC Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia.
BMJ Glob Health. 2024 Oct 21;9(10):e015245. doi: 10.1136/bmjgh-2024-015245.
A proportion of people develop Long Covid after acute COVID-19, but with most studies concentrated in high-income countries (HICs), the global burden is largely unknown. Our study aims to characterise long-term COVID-19 sequelae in populations globally and compare the prevalence of reported symptoms in HICs and low-income and middle-income countries (LMICs).
A prospective, observational study in 17 countries in Africa, Asia, Europe and South America, including adults with confirmed COVID-19 assessed at 2 to <6 and 6 to <12 months post-hospital discharge. A standardised case report form developed by International Severe Acute Respiratory and emerging Infection Consortium's Global COVID-19 Follow-up working group evaluated the frequency of fever, persistent symptoms, breathlessness (MRC dyspnoea scale), fatigue and impact on daily activities.
Of 11 860 participants (median age: 52 (IQR: 41-62) years; 52.1% females), 56.5% were from HICs and 43.5% were from LMICs. The proportion identified with Long Covid was significantly higher in HICs vs LMICs at both assessment time points (69.0% vs 45.3%, p<0.001; 69.7% vs 42.4%, p<0.001). Participants in HICs were more likely to report not feeling fully recovered (54.3% vs 18.0%, p<0.001; 56.8% vs 40.1%, p<0.001), fatigue (42.9% vs 27.9%, p<0.001; 41.6% vs 27.9%, p<0.001), new/persistent fever (19.6% vs 2.1%, p<0.001; 20.3% vs 2.0%, p<0.001) and have a higher prevalence of anxiety/depression and impact on usual activities compared with participants in LMICs at 2 to <6 and 6 to <12 months post-COVID-19 hospital discharge, respectively.
Our data show that Long Covid affects populations globally, manifesting similar symptomatology and impact on functioning in both HIC and LMICs. The prevalence was higher in HICs versus LMICs. Although we identified a lower prevalence, the impact of Long Covid may be greater in LMICs if there is a lack of support systems available in HICs. Further research into the aetiology of Long Covid and the burden in LMICs is critical to implement effective, accessible treatment and support strategies to improve COVID-19 outcomes for all.
急性 COVID-19 后,一部分人会出现长期新冠病毒感染,但由于大多数研究集中在高收入国家(HICs),因此全球负担在很大程度上尚不清楚。我们的研究旨在描述全球范围内长期 COVID-19 后遗症,并比较 HICs 和低收入和中等收入国家(LMICs)报告症状的患病率。
这是一项在非洲、亚洲、欧洲和南美洲 17 个国家进行的前瞻性、观察性研究,包括在住院后 2 至<6 个月和 6 至<12 个月时评估的确诊 COVID-19 成人。由国际严重急性呼吸和新兴感染联盟的全球 COVID-19 随访工作组制定的标准化病例报告表评估了发热、持续症状、呼吸困难(MRC 呼吸困难量表)、疲劳和对日常活动的影响的频率。
在 11860 名参与者中(中位年龄:52(IQR:41-62)岁;52.1%为女性),56.5%来自 HICs,43.5%来自 LMICs。在两个评估时间点,HICs 中确定患有长期新冠病毒感染的比例明显高于 LMICs(69.0% vs 45.3%,p<0.001;69.7% vs 42.4%,p<0.001)。与 LMICs 相比,HICs 的参与者更有可能报告未完全康复(54.3% vs 18.0%,p<0.001;56.8% vs 40.1%,p<0.001)、疲劳(42.9% vs 27.9%,p<0.001;41.6% vs 27.9%,p<0.001)、新/持续发热(19.6% vs 2.1%,p<0.001;20.3% vs 2.0%,p<0.001),焦虑/抑郁的患病率更高,且对日常活动的影响更大,分别在 COVID-19 住院后 2 至<6 个月和 6 至<12 个月。
我们的数据表明,长期新冠病毒感染影响着全球人口,在 HIC 和 LMIC 中表现出相似的症状和对功能的影响。在 HICs 中的患病率高于 LMICs。尽管我们发现患病率较低,但如果 HICs 缺乏支持系统,长期新冠病毒感染对 LMICs 的影响可能更大。进一步研究长期新冠病毒感染的病因和 LMICs 的负担对于实施有效的、可及的治疗和支持策略以改善所有 COVID-19 患者的结局至关重要。